JOINN Laboratories (China) Co., Ltd. (06127.HK) Latest Company News

Oct 29, 2026, 09:19 UTC
Joinn Laboratories, Joinn Biologics and Sheng Tong Intelligence signed a strategic cooperation agreement with Jointown Pharmaceutical Group to collaborate on drug research and sales, early-stage project investment, AI healthcare and a biopharmaceutical industrial park.
Source:
- finance.sina.cn
Oct 29, 2026, 08:26 UTC
Jointown Pharmaceutical Group signed a three-year strategic cooperation agreement with WuXi AppTec, WuXi AppTec's subsidiary, and Sheng Tong Intelligence to cooperate in drug research and sales, early-stage investment, AI healthcare, and biopharmaceutical industrial parks.
Source:
- finance.sina.cn
Oct 29, 2026, 04:33 UTC
Beijing Zhaoyan Biotech Technology Co., Ltd. and Beijing Jitai Life Science Co., Ltd. jointly established Zhaotai Zhiyào (Beijing) Technology Co., Ltd., with registered capital of 54.31 million yuan.
Source:
- finance.sina.cn
Oct 10, 2026, 06:48 UTC
Joinn Laboratories and other shareholders established Zhāoyǎn Shēngtóng Intelligent Technology (Beijing) Co., Ltd., whose business scope includes AI hardware sales, AI software development, data processing and medical research.
Source:
- finance.sina.cn
Sep 8, 2026, 13:51 UTC
On September 8, 2026, Joinn Laboratories held its 2026 interim results briefing, reporting H1 2026 revenue of 704 million yuan (up 5.27% year-on-year) and net profit attributable to shareholders of 748 million yuan (up 1126.8% year-on-year), driven largely by a 735 million yuan fair value gain on biological assets, while its core laboratory services business remained loss-making.
Source:
- wap.eastmoney.com
Aug 28, 2026, 08:55 UTC
Joinn Laboratories released its 2026 interim report on August 28, reporting net profit attributable to shareholders of 748 million yuan, up 1126.8% year-on-year, and revenue of 704 million yuan, up 5.27% year-on-year.
Source:
- aastocks.com
- aastocks.com
Jul 15, 2026, 01:50 UTC
Joinn Laboratories (06127) issued a profit alert, expecting a significant increase in net profit for the first half of 2026 due to a rise in biological asset market prices.
Source:

06127.HK

Joinn Laboratories, Joinn Biologics and Sheng Tong Intelligence signed a strategic cooperation agreement with Jointown Pharmaceutical Group to collaborate on drug research and sales, early-stage project investment, AI healthcare and a biopharmaceutical industrial park.

Jointown Pharmaceutical Group signed a three-year strategic cooperation agreement with WuXi AppTec, WuXi AppTec's subsidiary, and Sheng Tong Intelligence to cooperate in drug research and sales, early-stage investment, AI healthcare, and biopharmaceutical industrial parks.

Beijing Zhaoyan Biotech Technology Co., Ltd. and Beijing Jitai Life Science Co., Ltd. jointly established Zhaotai Zhiyào (Beijing) Technology Co., Ltd., with registered capital of 54.31 million yuan.

Joinn Laboratories and other shareholders established Zhāoyǎn Shēngtóng Intelligent Technology (Beijing) Co., Ltd., whose business scope includes AI hardware sales, AI software development, data processing and medical research.

Joinn Laboratories released its 2026 interim report on August 28, reporting net profit attributable to shareholders of 748 million yuan, up 1126.8% year-on-year, and revenue of 704 million yuan, up 5.27% year-on-year.

Joinn Laboratories (06127) issued a profit alert, expecting a significant increase in net profit for the first half of 2026 due to a rise in biological asset market prices.